Press release
Schizophrenia Clinical Trials Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Schizophrenia Treatment Landscape. Click here to read more @ Schizophrenia Pipeline Outlook [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Schizophrenia Pipeline Report
* In June 2025, Bristol-Myers Squibb announced a study With a 5-week Double-blind Part (Randomized, Parallelgroup, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia.
* In June 2025, Teva Branded Pharmaceutical Products R&D Inc . conducted a study will be composed of 2 periods: Period 1 (the double-blind, placebo-controlled, efficacy and safety period) and Period 2 (open-label long term safety period). For each participant, the duration of Period 1 will be 8 weeks, and the duration of Period 2 will be up to 48 weeks. In Period 1, participants will be randomized to one of 3 TV-44749 treatment groups or a placebo group in a 1:1:1:1 ratio.
* DelveInsight's Schizophrenia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Schizophrenia treatment.
* The leading Schizophrenia Companies such as Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
* Promising Schizophrenia Therapies such as x Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
Stay informed about the cutting-edge advancements in Schizophrenia treatments. Download for updates and be a part of the revolution in cancer care @ Schizophrenia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Schizophrenia Emerging Drugs Profile
* Ulotaront: Sunovion Pharmaceuticals
SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Currently, the drug is in the Phase III stage of its development for the treatment of Schizophrenia
* Emraclidine: Abbvie
Emraclidine is a selective M4 receptor PAM, meaning it selectively targets the M4 receptor to harness the anti-psychotic effect believed to be associated with this receptor while minimizing the side effects associated with other pan-muscarinic agonists. The company believes emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development. Currently, the drug is in the Phase II stage of its development for the treatment of Schizophrenia.
* CY 6463: Cyclerion Therapeutics
CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. As an sGC stimulator, CY6463 acts as a positive allosteric modulator to sensitize the sGC enzyme to NO, increase the production of cGMP, and thereby amplify endogenous NO signaling. By compensating for deficient NO-sGC-cGMP signaling, CY6463 and other sGC stimulators may have broad therapeutic potential as a treatment to improve cognition and function in people with serious CNS diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Schizophrenia.
Learn more about Schizophrenia Drugs opportunities in our groundbreaking Schizophrenia Research and development projects @ Schizophrenia Unmet Needs [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Schizophrenia Companies
Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Schizophrenia Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Schizophrenia treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Schizophrenia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Schizophrenia Pipeline Report
* Coverage- Global
* Schizophrenia Companies- Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
* Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others
* Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Schizophrenia Pipeline on our website @ Schizophrenia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Schizophrenia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Schizophrenia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* LYN-005: Lyndra Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Emraclidine: Abbvie
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* KYN-5356: Kynexis
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Schizophrenia Key Companies
* Schizophrenia Key Products
* Schizophrenia- Unmet Needs
* Schizophrenia- Market Drivers and Barriers
* Schizophrenia- Future Perspectives and Conclusion
* Schizophrenia Analyst Views
* Schizophrenia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=schizophrenia-clinical-trials-appears-robust-with-55-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/undefined
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Schizophrenia Clinical Trials Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4078717 • Views: …
More Releases from ABNewswire
Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Eme …
The 7MM Polycythemia Vera market size reached approximately USD 2 billion in 2024 and is projected to grow significantly through 2034. Key players such as Incyte, PharmaEssentia, Protagonist Therapeutics, Merck, Italfarmaco, Ionis Pharmaceuticals, Silence Therapeutics, Perseus Proteomics, AbbVie, J&J, Mabwell, GluBio Therapeutics, and others are spearheading innovations in treatment approaches, addressing critical unmet needs in managing this chronic myeloproliferative neoplasm.
DelveInsight's report, titled "Polycythemia Vera Market Insight, Epidemiology and Market Forecast…
Turn Clients into Referral Partners: LezDo TechMed Reveals Referral-Boosting Tac …
Image: https://www.abnewswire.com/upload/2025/06/0650e44860583acd0f11774a8d988d4d.jpg
LezDo TechMed, a leading litigation support service provider, has released new insights to help Independent Medical Examiners (IMEs) and Qualified Medical Evaluators (QMEs) unlock growth by tapping into an often underused resource resource: their existing clients.
With the increasing competition in the medical evaluation field, finding cost-effective ways to grow a practice is more important than ever. LezDo TechMed's new strategy outlines how evaluators can turn satisfied clients, such as…
SiyanoAV Antivirus: The Trusted Cybersecurity Solution for Small Businesses and …
Image: https://www.abnewswire.com/upload/2025/06/e919a5ad26622108d6c31bcc98b548f4.jpg
In an era where malware, ransomware, and phishing threats loom large, ordinary Windows users and growing businesses can't afford to underprotect their digital environment. Low-cost, lightweight antivirus solutions often fail to deliver crucial protection-or they significantly slow systems down. That's where SiyanoAV Antivirus [https://www.siyanoav.com/] steps in as a smarter choice.
1. Fast, Powerful Protection Without the Drag
* Real-time threat scanning intercepts malware, spyware, and ransomware the moment they appear-without…
Peripheral Arterial Disease Clinical Trials Trials, Companies, Therapeutic Asses …
DelveInsight's, "Peripheral Arterial Disease (PAD)- Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Peripheral Arterial Disease (PAD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Peripheral Arterial Disease Pipeline constitutes 20+ key companies continuously working towards developing 22+ Peripheral Arterial Disease treatment…
More Releases for Schizophrenia
Schizophrenia Treatment Market Volume Analysis 2016-2026
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and…
Schizophrenia Treatment Market size and forecast-2026
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and…
Technological Advancements to Influence Schizophrenia Treatment Market Growth
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and…
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could…
Global Schizophrenia Drug Market Research Report 2017
Qyresearchreports include new market research report "Schizophrenia Drug" to its huge collection of research reports.
The report on the Schizophrenia Drug deals with the all its critical facts and figures that will help in creating an in-depth and insightful analysis. The market is elucidated in a holistic fashion that allows the users to gain a thorough analysis of the market, as developed using the factors that are likely to have a…
Schizophrenia Drug Market Trends To 2022
Global Schizophrenia Drug Industry 2021 Market Research Report analyzed the current state in the definitions, classifications, applications and industry chain structure. The report also focuses on the development trends as well as history, competitive landscape analysis, and key regions etc in the international markets.
Global Schizophrenia Drug Industry 2021 Market Research Report is a professionally prepared report comprising of in-depth information as well as knowledge which is helpful to the new…
